The First-in-Human (FIH) study for a new pharmaceutical has immense significance. It represents the end of extensive nonclinical investigations and a critical hurdle to commencing large clinical studies to establish efficacy and safety. The significance for study participants, sponsors, nonclinical researchers, the clinical research organization responsible for undertaking the study, and the human research ethics committee cannot be overstated. Increasing economic pressures have resulted in a continuous and successful effort toward more efficient and cost-effective development of medicines to optimize returns before patent expiry. FIH studies have not escaped these pressures to shorten not only the duration of studies but also the desire to learn as much as possible about the new medicine, especially if it is a "new chemical entity" or equivalent, at the earliest opportunity.
The classical role of the FIH study was to establish a safe dose to be able to proceed to phase II studies to establish doseresponse relationships and the optimal dose regimens to take forward to the pivotal phase III studies. The temptation to undertake increasingly detailed pharmacokinetic (PK) and pharmacodynamic (PD) studies as part of FIH studies has been an increasingly common feature of FIH studies, such that overlap with classic phase II studies is very evident. A background concern is always the safety of participants in FIH studies, and whether these developments detract from that focus. New innovative pharmaceuticals have become more precise and act on increasingly fundamental components of physiological processes such as cellular "turn-over" mechanisms and immune and inflammatory reactions, thereby increasing the risk for effects that are unanticipated on the basis of results from nonclinical studies.
Despite a remarkable record of safety for participants in FIH studies, catastrophic reactions in the last decade, including a TeGenero AG product in 2006 and a Bial-Portela & Ca, SA, product in 2016, have rightly rung alarm bells and directed attention to all aspects of FIH studies and whether their prime responsibility of safety of participants is being compromised. Further, the better question, that is, whether the safety of participants has actually been enhanced by better risk assessment, is also being addressed, as exemplified by the Special Section of papers in this issue of Therapeutic Innovation & Regulatory Science.
Clinical Pharmacology Units and clinical research professionals have the responsibility of designing, approving, and undertaking FIH studies because of their education, training, and particular knowledge regarding pharmacology, clinical medicine, trial design and analysis, dose response relationships, and clinical toxicology. Accordingly, DIA's Clinical Pharmacology Community took a leadership role by highlighting FIH studies at the DIA 2016 Global Annual Meeting. The Community assembled an important collection of perspectives on FIH studies and the safety of individuals participating in these trials.
A discussion that focused on the Bial-Portela study examined the trial design in the context of nonclinical information as well as the processes of the trial from a number of perspectives. These discussions are summarized by Greenberg et al. This paper has been supplemented by an instructive presentation by Smith and Alcorn on "special populations" that are now required for very early-phase studies. Increasingly, patients with chronic organ impairments, particularly renal impairment, are needed to understand dosing requirements for patients with this organ failure. These studies require deep understanding of the clinical condition and the additional risks for these individuals involved in FIH studies. Can we assess risk for FIH trial subjects better in the light of the TeGenero and Bial-Portela incidents is the question posed by Van Iersel et al, whose paper provides an excellent and comprehensive approach to enhancing risk assessment for participants. Another excellent analysis of critical or "hot button" protocol and operational issues to be considered between sponsors and clinical pharmacology trial sites is provided by Steinman et al, whose paper summarizes a spirited, moderated expert panel and audience discussion also held at the DIA 2016 Global Annual Meeting. More about safety issues in FIH studies will be discussed at the upcoming DIA 2017 Global Annual Meeting, to be held June 18-22 in Chicago, USA.
The Clinical Pharmacology Community, led by Howard Greenberg and Stacie Bell, is to be commended for orchestrating this outstanding collection of papers addressing FIH studies and their safety for research participants: it is essential reading for those involved in this critical activity in medicine and device development.
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